S&P 500   4,567.00
DOW   34,483.72
QQQ   393.82
S&P 500   4,567.00
DOW   34,483.72
QQQ   393.82
S&P 500   4,567.00
DOW   34,483.72
QQQ   393.82
S&P 500   4,567.00
DOW   34,483.72
QQQ   393.82
OTCMKTS:WXXWY

WuXi Biologics (Cayman) Stock Forecast, Price & News

$27.05
-0.04 (-0.15%)
(As of 11/30/2021 12:00 AM ET)
Add
Compare
Today's Range
$26.51
$27.41
50-Day Range
$24.20
$32.52
52-Week Range
$19.39
$38.00
Volume
259,444 shs
Average Volume
218,795 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A
30 days | 90 days | 365 days | Advanced Chart
Receive WXXWY News and Ratings via Email

Sign-up to receive the latest news and ratings for WuXi Biologics (Cayman) and its competitors with MarketBeat's FREE daily newsletter.


WuXi Biologics (Cayman) logo

About WuXi Biologics (Cayman)

WuXi Biologics (Cayman) Inc., an open-access biologics technology platform company, provides solutions to organizations to discover, develop, and manufacture biologics from concept to commercial manufacturing in the People's Republic of China, North America, Europe, and internationally. The company also engages in the provision of consultation services in relation to the biopharmaceutical technology, international sales contracting services, testing and development of testing technologies, sales and marketing services, and biologics clinical and manufacturing services; production and sales of medicals; vaccine CDMO and related business; and material supplier activities. It has strategic partnerships with Almirall, S.A.; Vir Biotechnology, Inc.; Aravive, Inc.; Tubulis GmbH; Arcus Biosciences, Inc.; AC Immune SA; and AB2 Bio Ltd. The company was incorporated in 2014 and is headquartered in Wuxi, China. WuXi Biologics (Cayman) Inc. is a subsidiary of WuXi Biologics Holdings Limited.

Headlines

WuXi Biologics (Cayman) Inc. (OTCMKTS:WXXWY) Short Interest Update
November 17, 2021 |  americanbankingnews.com
WuXi Biologics Reports Strong 2021 Interim Results
August 23, 2021 |  finance.yahoo.com
WuXi Biologics (Cayman) Inc. (WXXWY)
June 18, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:WXXWY
CIK
N/A
Phone
N/A
Fax
N/A
Employees
6,646
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A

Profitability

Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Optionable
Not Optionable

MarketRank

Overall MarketRank

0.99 out of 5 stars

Analyst Opinion: 0.0Community Rank: 4.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -












WuXi Biologics (Cayman) (OTCMKTS:WXXWY) Frequently Asked Questions

Is WuXi Biologics (Cayman) a buy right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for WuXi Biologics (Cayman) in the last twelve months. There are currently 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "strong buy" WuXi Biologics (Cayman) stock.
View analyst ratings for WuXi Biologics (Cayman)
or view top-rated stocks.

How has WuXi Biologics (Cayman)'s stock been impacted by COVID-19?

WuXi Biologics (Cayman)'s stock was trading at $31.3225 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, WXXWY stock has decreased by 13.6% and is now trading at $27.05.
View which stocks have been most impacted by COVID-19
.

Are investors shorting WuXi Biologics (Cayman)?

WuXi Biologics (Cayman) saw a increase in short interest in the month of November. As of November 15th, there was short interest totaling 113,900 shares, an increase of 574.0% from the October 31st total of 16,900 shares. Based on an average daily volume of 414,800 shares, the short-interest ratio is presently 0.3 days.
View WuXi Biologics (Cayman)'s Short Interest
.

Who are WuXi Biologics (Cayman)'s key executives?

WuXi Biologics (Cayman)'s management team includes the following people:
  • Dr. Ge Li, Founder & Chairman (Age 54)
  • Dr. Zhisheng Chen, CEO & Exec. Director (Age 48, Pay $702.36k)
  • Dr. Weichang Zhou, Exec. VP, CTO & Exec. Director (Age 57, Pay $375.99k)
  • Ms. Shaohua Lu-Wong, Chief Financial Officer (Age 52)
  • Dr. Jijie Gu, Exec. VP & Chief Scientific Officer (Age 55)
  • Ms. Eileen Wang, IR Sr. Director
  • Ms. Tang Shaogui M.B.A., VP and Head of Global Corp. Communications & Public Affairs
  • Ms. Michelle M. Chen Ph.D., VP & Head of Corp. Devel.
  • Mr. Jian Dong, Sr. VP of Global Biomanufacturing (Age 57)
  • Mr. Angus Scott Marshall Turner, Sr. VP of Global Bus. Devel. & Alliance Management (Age 53)

What is WuXi Biologics (Cayman)'s stock symbol?

WuXi Biologics (Cayman) trades on the OTCMKTS under the ticker symbol "WXXWY."

How do I buy shares of WuXi Biologics (Cayman)?

Shares of WXXWY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is WuXi Biologics (Cayman)'s stock price today?

One share of WXXWY stock can currently be purchased for approximately $27.05.

How many employees does WuXi Biologics (Cayman) have?

WuXi Biologics (Cayman) employs 6,646 workers across the globe.

What is WuXi Biologics (Cayman)'s official website?

The official website for WuXi Biologics (Cayman) is www.wuxibiologics.com.cn.


This page was last updated on 12/1/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.